Becton, Dickinson & Stock News

BDX is now attractively valued with a forward PE of 13.7, well below its historical average, making it a compelling value stock. Strong growth in Pharmaceutical Systems and Interventional segments, margin expansion, and a robust innovation pipeline drive business momentum. The upcoming Waters Corp. spin-out will focus BDX on high-growth, recurring revenue segments, enhancing long-term earnings ...

Dividend Growth Outperformance: For over 50 years, dividend growers have delivered market-beating returns with lower volatility. The BTI Example: British American Tobacco went from six years of stagnation to 63% gains in 2025, beating the Mag 7 and Bitcoin—underscoring the power of patience. I've found 11 dividend aristocrats with 70%+ quality scores and 50+% justified 12-month return potential...

FRANKLIN LAKES, N.J. , Aug. 14, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025 at 8:00 a.m.

We remain patient and opportunistic, raising cash to capitalize on future volatility and focusing on stocks meeting our 10 Principles of Value Investing™. We initiated a position in Applied Materials, leveraging semiconductor industry weakness, and see secular tailwinds and potential for multiple expansion to the low $300s. Sensient Technologies delivered strong results on natural color demand,...

Dividend Aristocrat stocks are a select group of 69 stocks that have an unbroken track record of at least 25 consecutive years of dividend increases.

Becton, Dickinson and Company (NYSE:BDX ) Q3 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Christopher J. DelOrefice - Executive VP & CFO Greg Rodetis - Senior VP, Treasurer & Head of Investor Relations Thomas E.

Becton Dickinson raised its forecast for annual profit on Thursday, after beating Wall Street estimates for third-quarter profit and sales on strong demand for its drug-delivery devices.

Revenue of $5.5 billion increased 10.4% as reported, 8.5% adjusted FXN and 3.0% organic GAAP and adjusted diluted EPS grew to $2.00 and $3.68, respectively GAAP and adjusted gross margin up 160 basis points and 50 basis points, respectively, driven by BD Excellence GAAP and adjusted operating income up 46.6% and 11.3%, respectively Company raises full-year adjusted diluted EPS guidance to $14.3...